168 related articles for article (PubMed ID: 32323602)
21. Epidemiology of myeloproliferative neoplasms in the United States.
Mehta J; Wang H; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
[TBL] [Abstract][Full Text] [Related]
22. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Roaldsnes C; Holst R; Frederiksen H; Ghanima W
Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
24. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
[No Abstract] [Full Text] [Related]
25. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
[No Abstract] [Full Text] [Related]
26. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
27. Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Bao M; Zhang M; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Acta Haematol; 2023; 146(4):293-306. PubMed ID: 36812897
[TBL] [Abstract][Full Text] [Related]
28. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
29. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
30. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
31. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.
Byun JM; Kim YJ; Youk T; Yang JJ; Yoo J; Park TS
Ann Hematol; 2017 Mar; 96(3):373-381. PubMed ID: 28028559
[TBL] [Abstract][Full Text] [Related]
32. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
33. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
34. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
35. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.
Khan I; Shergill A; Saraf SL; Chen YF; Patel PR; Quigley JG; Peace D; Gordeuk VR; Hoffman R; Rondelli D
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):350-7. PubMed ID: 27052852
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
37. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
[TBL] [Abstract][Full Text] [Related]
38. Disease-Specific Derangement of Circulating Endocannabinoids and
Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
[TBL] [Abstract][Full Text] [Related]
39. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
[TBL] [Abstract][Full Text] [Related]
40. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]